POWER Point of Care Effect on Satisfaction of Treatment

Inclusion Criteria: * Women diagnosed with postmenopausal osteoporosis using community practice standards * Women previously non-treated for osteoporosis, OR treated for osteoporosis with biphosphonates (alendronate, etidronate), hormone replacement therapy estrogen, estrogen-related drugs, progesterone, subcutaneous estrogen implant), raloxifene, fluoride, or calcitonin within the past 2 years but discontinued prior to enrolment into the study either due to:lack of effect or intolerance Exclusion Criteria: * Subjects treated with Actonelr 5 mg daily, * Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study * Subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study * Known/Suspected hypersensitivity to any component of Actonelr 35 mg Once-a-Week * Known/Suspected hypocalcaemia * Known/Suspected severe renal impairment (creatinine clearance \< 30ml/min) * Known/Suspected hyperparathyroidism * Known/Suspected hyperthyroidism * Known/Suspected active urinary tract infection * Known high urine levels of calcium (3 4mg/ml) The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.